ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1530

Activin a and Follistatin Alter Endothelial Cell and Rheumatoid Arthritis Synovial Fibroblast Adhesion and Interaction
Abstract Number: 1576

Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review
Abstract Number: 0706

Adenosine A2A Receptor Activation Reduces Markers of Chondrocyte Senescence and Cartilage Inflammation Associated with Osteoarthritis
Abstract Number: 1477

Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
Abstract Number: 1593

Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus: Results of a Quality Improvement Initiative
Abstract Number: 0239

Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials
Abstract Number: 0047

Administrative Barriers to Enrollment of Ethnic Minorities in Clinical Research of Rheumatic/Immune-Mediated Diseases
Abstract Number: 1706

Advanced Integrated Science Courses: A Novel Approach to Medical Student Science Education
Abstract Number: 0933

Advanced Multiparametric Magnetic Resonance Imaging of Muscle for Detection and Quantification of Muscle Disease in Systemic Sclerosis
Abstract Number: 1830

Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Abstract Number: 2001

Adverse Effects of Low Dose Methotrexate: Adjudicated Hematologic Outcomes in a Large Randomized Double-blind Placebo-controlled Trial
Abstract Number: 1838

Aerobic Exercise Improves Fatigue and Quality of Life in Women with Systemic Lupus Erythematosus (Preliminary Analysis)
Abstract Number: 0395

African Ancestry-Specific Variants Regulate TGFB3 Expression in Systemic Sclerosis
Abstract Number: 0144

Age, Income, Education, and Health Conditions Are Associated with Patient Empowerment Among US Adults with Arthritis, but Race and Geography Are Not
Abstract Number: 0393

Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS)

« Previous Page
1
…
5
6
7
8
9
…
139
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].